Table 1.

ORs of response to platinum-based therapy for various clinicopathologic features

Clinical response
CharacteristicTotalYesNoOR95% CIPaGlobal Pb
All patients682543
Age
 <59461927
 ≥59226161.877(0.620–5.675)0.265
Gender
 Male501931
 Female186120.816(0.262–2.536)0.725
T stage
 221129
 3329233.407(1.070–10.847)0.038
 4154113.667(0.874–15.384)0.0760.073
N stage
 0391425
 112570.784(0.209–2.938)0.718
 2b8440.56(0.121–2.593)0.458
 2c4220.56(0.071–4.421)0.582
 35056.255(0.322–121.429)0.2260.404
N stage
 <2b511932
 ≥ 2b176111.089(0.346–3.422)0.885
TP53 status
 Wild-type422022
 Mutant265213.818(1.211–12.034)0.022
EA status
 Low risk542430
 High risk1411310.4(1.269–85.233)0.029
Poeta classification
 Non-disruptivec612437
 Disruptive7163.9(0.440–34.387)0.248

Abbreviations: CI, confidence interval; EA, evolutionary action score.

  • aUsed Fisher exact test to calculate P values.

  • bIf contingency table was larger than 2 × 2, then global P value was calculated using either χ2 test or Fisher exact test and P value was calculated for each 2 × 2 subtable. For comparison with the EAp53 system, patient tumors were also classified as disruptive and non-disruptive according to Poeta and colleagues (11).

  • cPatients with wild-type TP53 or silent mutations were classified as nondisruptive; however, the association was still not significant even when patients with wild-type TP53 or silent mutations were removed.